The association of serum anti-PLA2R antibody and glomerular PLA2R antigen staining with clinical manifestations and outcomes in membranous nephropathy
Authors:
- 5 September 2023
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (12) , 1060-1066
Abstract
Background Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) was manifested as seropositive for PLA2R antibodies (SAb) and/or glomerular PLA2R antigens’ (GAg) deposits. According to the test of SAb and GAg, PLA2R-associated MN can be divided into SAb + /GAg−, SAb−/GAg + , and SAb + /GAg + groups. The clinical characteristics and outcomes of the three groups need to be further evaluated. Methods 184 PLA2R-associated MN patients were enrolled. SAb was measured by enzyme-linked immunosorbent assay with a cut-off value of 14 RU/mL. GAg was detected by immunofluorescence using a paraffin section of renal biopsy samples. Clinical characteristics and the decline of eGFR were compared among the 3 groups. Results There were 33 SAb + /GAg−, 46 SAb−/GAg +, and 105 SAb + /GAg + PLA2R-associated MN patients reviewed. Clinical characteristics, such as the level of proteinuria, serum albumin, as well as eGFR, were comparable between the SAb + /GAg− and SAb + /GAg + patients. While SAb−/GAg + patients exhibited mild clinical manifestations as evidenced by higher serum albumin (P < 0.001) and lower proteinuria (p = 0.049) compared with SAb + /GAg + patients. After 21.96 ± 7.39 month follow-up, the eGFR decrease was no difference between the SAb + /GAg− and SAb + /GAg + patients. SAb−/GAg + patients had a lower rate of the > 20% eGFR decline as well as a 50% eGFR decline compared with the SAb + /GAg + patients (10.87% vs 30.48%, p = 0.013; 0.00% vs 4.76%, p = 0.324). Conclusions Our study showed that the clinical manifestations of SAb + /Gag− patients were the same as those of double-positive patients, while SAb−/GAg + patients exhibited mild clinical manifestations and slower eGFR decline compared to the double-positive patients.Keywords
Funding Information
- Natural Science Foundation of Shaanxi Province (2020JQ-500)
This publication has 14 references indexed in Scilit:
- Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathyNephrology, 2019
- Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous NephropathyAmerican Journal of Nephrology, 2018
- Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathyMedicine, 2017
- Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)Autoimmunity Reviews, 2016
- Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous NephropathyBioMed Research International, 2015
- AJKD Atlas of Renal Pathology: Membranous NephropathyAmerican Journal of Kidney Diseases, 2015
- Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathyKidney International, 2012
- PLA2R Autoantibodies and PLA2R Glomerular Deposits in Membranous NephropathyNew England Journal of Medicine, 2011
- M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous NephropathyNew England Journal of Medicine, 2009
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009